<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589950</url>
  </required_header>
  <id_info>
    <org_study_id>Anlo01</org_study_id>
    <nct_id>NCT03589950</nct_id>
  </id_info>
  <brief_title>Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Parallel Control, Exploratory Trial to Compare Anlotinib Plus Chemotherapy Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First People's Hospital of Lianyungang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First People's Hospital of Lianyungang</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug
      Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
      multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance
      to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of
      advanced non-small cell lung cancer who failed first lines of chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCR</measure>
    <time_frame>Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Disease Control Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From randomization until death (up to 24 months)</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>each 21 days up to the toxicity or PD (up to 24 months)</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>each 21 days up to the toxicity or PD (up to 24 months)</time_frame>
    <description>Quality of life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>each 21 days up to the toxicity or PD (up to 24 months)</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Docetaxel</condition>
  <condition>Pemetrexed</condition>
  <condition>S-1</condition>
  <condition>Anlotinib</condition>
  <arm_group>
    <arm_group_label>Anlotinib plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anlotinib plus chemotherapy</intervention_name>
    <description>Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)</description>
    <arm_group_label>Anlotinib plus chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age：18~75 years;

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 -2

          3. Subjects with histologically or cytologically confirmed locally advanced or advanced
             NSCLC who have previously received one lines chemotherapy, EGFR TKI or ALK inhibitor
             (whom with EGFR or ALK mutation but not with T790 M positive) treatment before
             participating；

          4. Subjects with at least one measurable lesion as defined by RECIST (version 1.1),which
             is confirmed by computed tomography (CT) scan or MRI .

          5. Subjects without brain metastases or asymptomatic brain metastases, and not needing
             for dehydrating agents or corticosteroids to control intracranial symptoms;

          6. Survival expectation ≥ 3 months;

          7. The main organ function is normal;

          8. Females of childbearing potential must be a pregnancy test in 7 days before
             participating ( including serum or urine), and the results were negative.

          9. Subjects provided written informed consent before participating, willing and able to
             comply with all aspects of the protocol

        Exclusion Criteria:

        1. Small Cell Lung Cancer; 2. Subjects with symptomatic brain metastases; 3. Survival
        expectation ＜ 3 months; 4. examined as positive in EGFR&amp;ALK mutation detection and never
        take the treatment of TKIs 5. Blood transfusion is required in the first dose of drug
        treatment within 14 days ; 6. The interval of subjects had received chemotherapy,
        biotherapy, radiotherapy or other anticancer therapies in the first dose of drug treatment
        within 21 days(excluding palliative radiotherapy); 7. The risk of active bleeding; 8.
        Subjects with uncontrolled blood pressure with medication (140/90 mmHg) 9. Laboratory
        values and organ functions ： （1）Hematologic insufficiency:

          1. Hemoglobin (Hb)&lt;8.5 g/dL，

          2. Absolute neutrophil count (ANC)≤1.5×109/L，

          3. Platelet count (PLT)&lt; 100×109/L； （2）Insufficient liver function:

          4. Bilirubin &gt; 1.5×the upper limit of normal (ULN)

          5. Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) &gt;3.0×(ULN), When
             liver metastases,Bilirubin &gt; 1.5×ULN, ALT or AST &gt;5.0×(ULN.

          6. serum creatinine ≤1.0×（ULN）, or creatinine clearance &gt; 50 mL/min( calculated per the
             Cockcroft and Gault formula) (3) Subjects with positive for HBV surface antigen (
             HBsAg)or anti-hcv (4)Subjects with Interstitial lung disease (5)Insufficient renal
             function: serum creatinine≥ 1.5×（ULN）, or creatinine clearance &lt;60 mL/min

        10. impairment of heart function: (1)Left ventricular ejection fraction (LVEF) &lt;45% (LVEF
        evaluation is not required for subjects have no history of congestive heart failure),
        (2)Unstable angina, (3)Severe arrhythmia, (4)NYHA III or IVgrade of congestive heart
        failure, (5) Subjects with myocardial infarction within the last 12 months before entering
        the trial, (6)Pericardial effusion, 11. Subjects with liver fibrosis or hepatic cirrhosis
        12. (1)Subjects with other active malignancy (except for definitively treated non melanoma
        skin cancer,carcinoma in-situ of the cervix,or other cancers that are treated with curative
        treatment and have no signs of recurrence for at least 5 years ) , (2)Subjects with
        dysphagia,malabsorption,chronic gastrointestinal diseases,or other medical history may
        hinder compliance and / or experimental drug absorption, 13. Subjects with major surgery in
        the first dose of drug treatment within 28 days, 14. Subjects with positive unknown human
        immunodeficiency virus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaodong jiang, MD</last_name>
    <phone>18961326201</phone>
    <email>jxdysy1970@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Lianyungang Hospital of Xuzhou Medical University</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222002</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>xiaodong jiang, MD</last_name>
      <phone>18961326201</phone>
      <email>jxdysy1970@163.com</email>
    </contact>
    <investigator>
      <last_name>lijun liang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>yixuan wen, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018 Apr;109(4):1207-1219. doi: 10.1111/cas.13536. Epub 2018 Mar 25.</citation>
    <PMID>29446853</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016 Oct 4;9(1):105.</citation>
    <PMID>27716285</PMID>
  </reference>
  <reference>
    <citation>Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, Luo Y, Zhang Y, Huang C, Li Q, Wu G. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13.</citation>
    <PMID>29438373</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anlotinib</keyword>
  <keyword>docetaxel</keyword>
  <keyword>pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

